Bosh sahifaPHS • FRA
add
Photocure ASA
Yopilish kursi
4,64 €
Kunlik diapazon
4,41 € - 4,41 €
Yillik diapazon
3,97 € - 5,63 €
Oʻrtacha hajm
13,00
Narx/foyda
-
Dividend daromadliligi
-
Bozor yangiliklari
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (NOK) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | 125,34 mln | 6,18% |
Joriy xarajat | 121,77 mln | 11,16% |
Sof foyda | -2,41 mln | 69,44% |
Sof foyda marjasi | -1,92 | 71,26% |
Har bir ulushga tushum | -0,09 | 68,97% |
EBITDA | 318,00 ming | -95,96% |
Amaldagi soliq stavkasi | 74,31% | — |
Balans
Jami aktivlari
Jami passivlari
| (NOK) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 259,54 mln | 0,49% |
Jami aktivlari | 708,56 mln | -0,85% |
Jami passivlari | 236,71 mln | 2,24% |
Umumiy kapital | 471,85 mln | — |
Tarqatilgan aksiyalar | 26,65 mln | — |
Narxi/balansdagi bahosi | 0,26 | — |
Aktivlardan daromad | -1,93% | — |
Kapitaldan daromad | -2,81% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (NOK) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -2,41 mln | 69,44% |
Operatsiyalardan naqd pul | 4,07 mln | -51,46% |
Sarmoyadan naqd pul | 657,00 ming | 303,07% |
Moliyadan naqd pul | -39,04 mln | -299,12% |
Naqd pulning sof oʻzgarishi | -34,31 mln | -2 682,81% |
Boʻsh pul | 8,38 mln | 15,47% |
Haqida
Photocure ASA is a Norwegian specialty pharma company that develops and sells pharmaceuticals and medical devices based on proprietary photodynamic technology. Photocure's strategy in cancer is to continue the commercialization of Hexvix for bladder cancer diagnostics, and continue the development of the cancer portfolio and out-license prior to phase III studies. This strategy is based on a strong platform of intellectual property in photodynamic therapy. Wikipedia
Tashkil etilgan
1993
Sayt
Xodimlar soni
100
